Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lean body mass

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    131 result(s) found for: Lean body mass. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2006-006354-98 Sponsor Protocol Number: L00074 TD 304 Start Date*: 2007-06-07
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: “Transdermal testosterone supplementation in elderly hypogonadal men with sarcopenia: effects on muscle function, physical performance, body composition and quality of life.” A randomized, double-b...
    Medical condition: ELDERLY HYPOGONADAL MEN WITH SARCOPENIA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063024 Sarcopenia LLT
    Population Age: Elderly Gender: Male
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-009155-37 Sponsor Protocol Number: 2008/066/HP Start Date*: 2010-09-07
    Sponsor Name:CHU-HOPITAUX DE ROUEN
    Full Title: Evaluation of the impact of physical reconditioning associated with specific nutritional supplementation in obese patients suffering of metabolic syndrome.
    Medical condition: Obese patients suffering of metabolic syndrome
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000377-20 Sponsor Protocol Number: VK5211-201 Start Date*: 2016-05-27
    Sponsor Name:Viking Therapeutics, Inc.
    Full Title: A Phase II, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Multi-Center Study to Explore the Efficacy, Safety and Tolerability of VK5211 in Subjects with Acute Hip Fracture
    Medical condition: Hip fracture
    Disease: Version SOC Term Classification Code Term Level
    19.0 10022117 - Injury, poisoning and procedural complications 10020100 Hip fracture PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003134-33 Sponsor Protocol Number: R1033-SRC-1239 Start Date*: 2014-01-31
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF 3-MONTH SUBCUTANEOUS REGN1033 TREATMENT IN PATIENTS WITH SARCOPENIA
    Medical condition: Sarcopenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10063024 Sarcopenia PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-003482-25 Sponsor Protocol Number: CBYM338E2202 Start Date*: 2015-01-30
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A 28 week, randomized, double-blind, placebo-controlled, multi-center, parallel group dose range finding study to assess the effect of monthly doses of bimagrumab 70, 210, and 700 mg on skeletal mu...
    Medical condition: sarcopenia
    Disease: Version SOC Term Classification Code Term Level
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10063024 Sarcopenia PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DK (Completed) BE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2016-004124-26 Sponsor Protocol Number: CBYM338X2211 Start Date*: 2017-09-16
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, subject- and investigator-blinded, placebo-controlled study to assess the safety, pharmacokinetics and efficacy of intravenous bimagrumab in overweight and obese patients with type 2 ...
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002333-21 Sponsor Protocol Number: 1 Start Date*: 2006-07-28
    Sponsor Name:Allgemeines Krankenhaus Wien, Medizinische Un iversität Wien [...]
    1. Allgemeines Krankenhaus Wien, Medizinische Un iversität Wien
    2. Allgemeines Krankenhaus Wien, Medizinische Universität Wien
    Full Title: Intraoperative Goal-Directed Fluid Therapy in Lean and Obese Patients
    Medical condition: Hemodynamics in obese patients differ from lean patients: Obese patients have a higher cardiac output, the absolute amount of their intravascular volume is increased, as is the intracellular volume...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003899-13 Sponsor Protocol Number: NL65803.078.18 Start Date*: 2018-12-20
    Sponsor Name:
    Full Title: The effect of IntraDialytic Parenteral Nutrition on nutritional status and quality of life in hemodialysis patients
    Medical condition: Malnutrition / Sarcopenia (loss of muscle mass) in hemodialyse patients.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004104-30 Sponsor Protocol Number: 307-MET-9002-0009 Start Date*: 2015-04-01
    Sponsor Name:Pharmacia & Upjohn S.A.
    Full Title: Treatment With Recombinant Human Growth Hormone (Genotonorm) in Children With Short Stature Secondary to a Long Term Corticoid Therapy. A Study of Efficacy and Safety
    Medical condition: Juvenile idiopathic arthritis (JIA) and nephrotic syndrome (NeS)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-023648-34 Sponsor Protocol Number: HT-ANAM-301 Start Date*: 2011-09-15
    Sponsor Name:Helsinn Therapeutics (U.S.), Inc.
    Full Title: Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer – Cachexia (NSCLC-C): A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Safety and Efficacy ...
    Medical condition: Non-Small Cell Lung Cancer related Cachexia (NSCLC-C)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10002646 Anorexia LLT
    14.1 10027433 - Metabolism and nutrition disorders 10064015 Cancer cachexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) ES (Completed) DE (Completed) CZ (Completed) IT (Completed) SI (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-000471-27 Sponsor Protocol Number: CBYM338E2202E1 Start Date*: 2015-10-15
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A 28 week randomized withdrawal extension of a doubleblind, placebo-controlled, parallel group study to assess durability of effect on skeletal muscle strength and function upon withdrawal of bimag...
    Medical condition: Sarcopenia
    Disease: Version SOC Term Classification Code Term Level
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10063024 Sarcopenia PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-023649-31 Sponsor Protocol Number: HT-ANAM-302 Start Date*: 2011-07-29
    Sponsor Name:Helsinn Therapeutics (U.S.), Inc.
    Full Title: Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer – Cachexia (NSCLC-C): A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Safety and Efficacy ...
    Medical condition: Non-Small Cell Lung Cancer related Cachexia (NSCLC-C)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10027433 - Metabolism and nutrition disorders 10002646 Anorexia LLT
    13.1 10027433 - Metabolism and nutrition disorders 10064015 Cancer cachexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2024-000101-32 Sponsor Protocol Number: A6281323 Start Date*: 2024-09-19
    Sponsor Name:Pfizer, Inc.
    Full Title: A PHASE 3 MULTICENTER, OPEN LABEL, MULTI COHORT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SOMATROPIN IN JAPANESE PARTICIPANTS WITH PRADER-WILLI SYNDROME (PWS)
    Medical condition: Prader-Willi Syndrome
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-002383-95 Sponsor Protocol Number: 0773-005-00 Start Date*: 2007-08-08
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Phase IIa Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0773 in Patients with Sarcopenia
    Medical condition: Sarcopenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063024 Sarcopenia LLT
    Population Age: Elderly Gender: Female
    Trial protocol: DK (Completed) ES (Completed) FR (Completed) GB (Completed) FI (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002102-73 Sponsor Protocol Number: 171178 Start Date*: 2012-02-17
    Sponsor Name:Endokrinologisk afd. M
    Full Title: Testosterone therapy of patients with type 2 diabetes mellitus
    Medical condition: Type 2 diabetes mellitus (T2DM) is a common endocrine disorder caracterized by hyperinsulinaemia and insulin resistance. We aim to investigate if testosterone therapy can improve body composition, ...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10043368 Testosterone decreased LLT
    14.1 10027433 - Metabolism and nutrition disorders 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-001001-28 Sponsor Protocol Number: G200501 Start Date*: 2006-05-04
    Sponsor Name:GTx Inc
    Full Title: Double-blind, placebo controlled, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of GTx-024 in Postmenopausal Females and Elderly Males
    Medical condition: Healthy volunteers (Postmenopausal Females and Elderly Males)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000705-23 Sponsor Protocol Number: CBYM338B2203 Start Date*: 2014-02-09
    Sponsor Name:Novartis Farma SpA
    Full Title: A randomized, double-blind, placebo-controlled, multicenter, parallel group, dose-finding, pivotal, phase IIb/III study to evaluate the efficacy, safety and tolerability of intravenous BYM338 at 52...
    Medical condition: Sporadic Inclusion Body Myositis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10066407 Inclusion body myositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) NL (Completed) DE (Completed) BE (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2004-001545-15 Sponsor Protocol Number: 307720 Start Date*: 2004-11-04
    Sponsor Name:Schering AG
    Full Title: Estudio multicéntrico, doble ciego, aleatorizado, controlado con placebo de Testogel® (testosterona 50–100mg) para evaluar su eficacia y seguridad en hombres que presentan síntomas típicos de defic...
    Medical condition: Déficit Androgénico parcial en la edad avanzada.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004216-22 Sponsor Protocol Number: C602 Start Date*: 2019-09-25
    Sponsor Name:Soleno Therapeutics UK Ltd.
    Full Title: An Open-Label, Long-Term Safety and Efficacy Evaluation of Diazoxide Choline Controlled-Release Tablet in Patients with Prader-Willi Syndrome
    Medical condition: Hyperphagia associated with Prader-Willi Syndrome (PWS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10020710 Hyperphagia PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2010-024342-30 Sponsor Protocol Number: CBYM338X2202 Start Date*: 2011-07-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled multi-center study of BYM338 for treatment of cachexia in patients with stage IV non-small cell lung cancer or stage III/IV adenocarcinoma of the panc...
    Medical condition: Condition of cachexia in adults with stage IV metastatic non-small cell lung cancer or stage III/IV pancreatic adenocarcinoma.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10064015 Cancer cachexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) LT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 15:31:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA